IDEAYA Biosciences Q1 Loss Widens, Misses Estimates on Higher R&D Spend
summarizeSummary
IDEAYA Biosciences reported a wider net loss for Q1 and missed analyst expectations across key financial metrics including EPS, net income, and profit from operations. Collaboration revenue also declined from the prior quarter. This financial performance contrasts with the improved 2025 results reported in the last 10-K. The increased R&D expenses driving the loss are attributed to higher clinical trial and personnel costs supporting pipeline programs. Positively, the company announced positive topline results from its Phase 2/3 darovasertib trial in uveal melanoma and maintained its cash runway guidance into 2030. Traders will weigh the financial miss against the significant clinical progress and continued financial stability, with the NDA filing for darovasertib in H2 2026 being a key upcoming catalyst.
At the time of this announcement, IDYA was trading at $28.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $16.82 to $39.28. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.